⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12374284 | 0.73 | — | — | |
| SCHEMBL413457 | 0.72 | — | — | |
| SCHEMBL21737612 | 0.72 | — | — | |
| SCHEMBL18212638 | 0.70 | — | — | |
| SCHEMBL17689166 | 0.69 | — | — | |
| SCHEMBL14208028 | 0.69 | PIK3CG (0.33) | — | |
| SCHEMBL12359820 | 0.69 | — | — | |
| SCHEMBL21721594 | 0.69 | ALDH1A1 (0.40) | — | |
| SCHEMBL15548863 | 0.68 | — | — | |
| SCHEMBL3323565 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| CN-114786778-A | Therapeutic compounds | 基因泰克公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021123294-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | WO | disclosed |
| EP-2114941-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-03-25 | — | — | EP | disclosed |
| EP-2114941-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-03-25 | — | — | EP | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| CN-101679408-A | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LTD | 2010-03-24 | — | — | CN | disclosed |
| US-20100004305-A1 | NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286842-A1 | NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| EP-2114941-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| US-20090048415-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
| US-20080293747-A1 | Chemical Synthesis of a Highly Potent Epothilone | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-11-27 | — | — | US | disclosed |
| WO-2008088937-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |